Within CLL, the mTOR pathway is differentially modulated in CLL patients from distinct cohorts with an elevation in 4EBP1 phosphorylation in poorer prognostic CLL patients. This evidence concerns the gene EIF4EBP1 and B-cell chronic lymphocytic leukemia.